A non-invasive diagnostics of cancers, such as bladder cancer, on the basis of altered glycosylation patterns of cancer-associated biomarkers, especially integrins.

The present invention relates to a method for diagnosing whether a subject may be at risk for or may suffer from cancer wherein (significantly) lower or (significantly) higher binding of a binding agent to a particular glycan structure of a biomarker glycoprotein compared to a control sample is indicative for said subject to be at risk for or to suffer from cancer. The present invention further relates to a kit for performing said for method of diagnosing whether a subject may be at risk for or may suffer from cancer, comprising a binding agent capable to bind to a glycan structure of a biomarker protein.

The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer.

Provided are compositions and methods of targeting imaging or therapeutic agents to cancer sites using Fap2. Also provided are methods of treating cancer by inhibiting the complexing of Fusobacterium nucleatum Fap2 and Gal-GalNAc molecules expressed on cancer cells.

The invention provides a method for predicting the clinical response to a cancer vaccine in a patient having cancer, a method for determining the immune response to a cancer vaccine in a patient having cancer who has been administered a cancer vaccine, a method for determining the long-term survival in a patient having cancer, corresponding kits therefor, as well as methods of for improving the efficacy of a virus-based vaccine.

This disclosure relates to a screening test method, device, and kit for mucosal carbohydrates and associated conditions including, cancerous and precancerous conditions. Specifically, the method tests abnormal carbohydrates in mucus or body fluid using reagents of galactose oxidase, and Schiff's Reagent. The screening test method, device, and kit provides improved accuracy, and minimizes handling procedures. This disclosure further relates to the use of the device or kit in a medical facility for an initial evaluation for cancerous and precancerous conditions.

Embodiments provide for anti-GPC3 antibodies compositions comprising the same, and methods of using such antibodies and compositions for the prevention, diagnosis, and treatment of cancer. In one embodiment, a method for predicting a therapeutic effect of an anti-GPC3 immunotherapy on a cancer characterized in that cells of the cancer express GPC3, comprises detecting the presence of said cells in a subject via an immunohistochemical methodology, and wherein when the presence of said cells is detected, the anti-GPC3 immunotherapy is predicted to have a therapeutic effect on the cancer in the subject.

The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.

The invention provides a method for predicting the clinical response to a cancer vaccine in a patient having cancer, a method for determining the immune response to a cancer vaccine in a patient having cancer who has been administered a cancer vaccine, a method for determining the long-term survival in a patient having cancer, corresponding kits therefor, as well as methods of for improving the efficacy of a virus-based vaccine.

Laboratory cancer diagnostics are disclosed. A set of reagents for detecting the marker for epithelial carcinomas CA-62 in patients' blood serum for early detection of cancer, detecting cancer recurrences and monitoring cancer treatment of human epithelial tumors using immunochemical analysis, is described. A difference between the CA-62 cancer marker and other well-known markers relates to the maximum peak of its expression failing on the very beginning of cancer development. This makes it possible to detect early stages of tumor growth with high sensitivity and specificity when the cure rate is at maximum. The dynamics of the CA-62 marker level show high efficacy in detecting tumor recurrences and monitoring the treatment of patients with advanced cancer. The set of reagents includes a microplate with immobilized antibodies to a CA-62 cancer antigen, CA-62-Acridinium conjugate, CA-62 standard calibrators from 10-30000 U/ml, CA-62 positive control, working buffer solution (pH 2.0-8.0) containing Tween-80.